The Relationship of Molecular Markers of p53 Function and Angiogenesis to Prognosis of Stage I Epithelial Ovarian Cancer
- 15 May 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (10) , 3733-3742
- https://doi.org/10.1158/1078-0432.ccr-04-0056
Abstract
Multiple angiogenic factors may influence tumor progression and metastasis. Several are modified by the p53 gene. We sought to identify molecular markers for high-risk stage I epithelial ovarian cancers. Seventy-seven consecutive stage I epithelial ovarian cancers were evaluated for p53, CD31 microvessel density, thrombospondin-1, vascular endothelial growth factor (VEGF), p21 immunohistochemical staining, and p53 gene mutations. Molecular marker impact upon disease-specific survival, disease recurrence, and distant recurrence was evaluated with Cox regression. There were 12 deaths from disease. Twelve of the 77 tumors contained p53 mutations-10 missense and 3 null (one tumor had two mutations). Fesddration Internationale des Gynaecologistes et Obstetristes substage (IA/IB versus IC; P < 0.001) and VEGF staining (P = 0.02) were significant in bivariate models with relationship to disease-specific survival. Stage (P = 0.0004), grade (P = 0.008), histology (P = 0.0025), p53 dysfunction (positive stain and/or mutation; P = 0.048), and microvessel density (P = 0.04) were significant in bivariate models with relationship to time to recurrence. In multivariate analyses among stage IC patients, failure to receive chemotherapy and microvessel density were associated with disease-specific survival, time to recurrence, and time to distant recurrence with hazard ratios of 4.8 to 44.1. The p53-dependent molecular markers of angiogenesis are of limited utility in developing a clinical strategy for postoperative management of stage I ovarian carcinoma. Microvessel density impacts survival and metastasis for high-risk stage IC disease. Adjuvant chemotherapy is necessary, but not sufficient, for cure of high-risk stage I epithelial ovarian cancers.Keywords
This publication has 37 references indexed in Scilit:
- Survival and prognostic factors in patients with ovarian cancerObstetrics & Gynecology, 2003
- International Collaborative Ovarian Neoplasm Trial 1: A Randomized Trial of Adjuvant Chemotherapy in Women With Early-Stage Ovarian CancerJNCI Journal of the National Cancer Institute, 2003
- The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapyInternational Journal of Gynecologic Cancer, 2002
- Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinomaThe Lancet, 2001
- Surgical staging of early invasive epithelial ovarian tumorsSeminars in Surgical Oncology, 2000
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEuropean Journal Of Cancer, 1996
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Can we predict a high risk group in stage I epithelial ovarian cancer?International Journal of Gynecologic Cancer, 1993
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958